A Framework for Assessing the Impact of Accelerated Approval

Author:

Gould A. LawrenceORCID,Campbell Robert K.,Loewy John W.,Beckman Robert A.,Dey Jyotirmoy,Schiel Anja,Burman Carl-Fredrik,Zhou Joey,Antonijevic Zoran,Miller Eva R.,Tang Rui

Abstract

AbstractThe FDA’s Accelerated Approval program (AA) is a regulatory program to expedite availability of products to treat serious or life-threatening illnesses that lack effective treatment alternatives. Ideally, all of the many stakeholders such as patients, physicians, regulators, and health technology assessment [HTA] agencies that are affected by AA should benefit from it. In practice, however, there is intense debate over whether evidence supporting AA is sufficient to meet the needs of the stakeholders who collectively bring an approved product into routine clinical care. As AAs have become more common, it becomes essential to be able to determine their impact objectively and reproducibly in a way that provides for consistent evaluation of therapeutic decision alternatives. We describe the basic features of an approach for evaluating AA impact that accommodates stakeholder-specific views about potential benefits, risks, and costs. The approach is based on a formal decision-analytic framework combining predictive distributions for therapeutic outcomes (efficacy and safety) based on statistical models that incorporate findings from AA trials with stakeholder assessments of various actions that might be taken. The framework described here provides a starting point for communicating the value of a treatment granted AA in the context of what is important to various stakeholders.

Publisher

Cold Spring Harbor Laboratory

Reference41 articles.

1. US Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics 2017 [Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf.

2. US Food and Drug Administration. CDER Drug and Biologic Acclerated Approvals Based on a Surrogate Endpoint (June 30, 2021) 2021 October 8, 2021. Available from: https://www.fda.gov/media/151146/download.

3. Expediting drug development for serious illness: Tradeoffs between patient access and certainty;Clinical Trials,2018

4. Current status of HIV/AIDS in the ART era

5. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review;JAMA Oncology,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3